• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Study: Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease

Shiloh

Editor, Senior Moderator
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2024670?af=R&rss=currentIssue

Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease
List of authors.

Placide Mbala-Kingebeni, M.D., Ph.D., Catherine Pratt, M.Sc., Mbusa Mutafali-Ruffin, M.D., Matthias G. Pauthner, Ph.D., Faustin Bile, M.D., Antoine Nkuba-Ndaye, M.D., Allison Black, Ph.D., Eddy Kinganda-Lusamaki, M.D., Martin Faye, Ph.D., Amuri Aziza, M.Sc., Moussa M. Diagne, Ph.D., Daniel Mukadi, M.D., Bailey White, B.Sc., James Hadfield, Ph.D., Karthik Gangavarapu, B.Pharm., Nella Bisento, M.Sc., Donatien Kazadi, M.D., Bibiche Nsunda, B.Sc., Marceline Akonga, B.Sc., Olivier Tshiani, M.D., John Misasi, M.D., Aurelie Ploquin, Ph.D., Victor Epaso, M.D., Emilia Sana-Paka, M.D., Yannick Tutu Tshia N?kasar, M.D., Fabrice Mambu, M.D., Francois Edidi, M.D., Meris Matondo, M.D., Junior Bula Bula, M.D., Boubacar Diallo, M.D., Mory Keita, M.D., Marie R.D. Belizaire, M.D., Ibrahima S. Fall, Ph.D., Abdoulaye Yam, M.D., Sabue Mulangu, M.D., Anne W. Rimion, Ph.D., M.P.H., Elias Salfati, Ph.D., Ali Torkamani, Ph.D., Marc A. Suchard, M.D., Ph.D., Ian Crozier, M.D., Lisa Hensley, Ph.D., Andrew Rambaut, Ph.D., Ousmane Faye, Ph.D., Amadou Sall, Ph.D., Nancy J. Sullivan, Ph.D., Trevor Bedford, Ph.D., Kristian G. Andersen, Ph.D., Michael R. Wiley, Ph.D., Steve Ahuka-Mundeke, M.D., Ph.D., and Jean-Jacques Muyembe Tamfum, M.D., Ph.D.

Summary

During the 2018?2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus?based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)?specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)...
 
Back
Top